keyword
MENU ▼
Read by QxMD icon Read
search

minimal residual disease

keyword
https://www.readbyqxmd.com/read/29165013/efficacy-and-safety-of-native-versus-pegylated-escherichia-coli-asparaginase-for-treatment-of-adults-with-high-risk-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia
#1
Josep-Maria Ribera, Mireia Morgades, Pau Montesinos, Rodrigo Martino, Pere Barba, Beatriz Soria, Arancha Bermúdez, María-José Moreno, José González-Campos, Susana Vives, Cristina Gil, Eugenia Abella, Ramon Guàrdia, Daniel Martínez-Carballeira, Pilar Martínez-Sánchez, María-Luz Amigo, Santiago Mercadal, Alfons Serrano, Aurelio López-Martínez, Ferran Vall-Llovera, María-José Sánchez-Sánchez, María-Jesús Peñarrubia, María Calbacho, Jose-Angel Méndez, Juan Bergua, Antonia Cladera, Mar Tormo, Daniel García-Belmonte, Evarist Feliu, Juana Ciudad, Alberto Orfao
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164966/minimal-residual-disease-detected-by-immunoglobulin-sequencing-predicts-cll-relapse-more-effectively-than-flow-cytometry
#2
Andrew Aw, Haesook T Kim, Stacey M Fernandes, Kevin Hoang, Siddha Kasar, Malek Faham, Jennifer R Brown
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164133/role-of-dietary-antioxidants-in-the-preservation-of-vascular-function-and-the-modulation-of-health-and-disease
#3
REVIEW
Saradhadevi Varadharaj, Owen J Kelly, Rami N Khayat, Purnima S Kumar, Naseer Ahmed, Jay L Zweier
In vascular diseases, including hypertension and atherosclerosis, vascular endothelial dysfunction (VED) occurs secondary to altered function of endothelial nitric oxide synthase (eNOS). A novel redox regulated pathway was identified through which eNOS is uncoupled due to S-glutathionylation of critical cysteine residues, resulting in superoxide free radical formation instead of the vasodilator molecule, nitric oxide. In addition, the redox sensitive cofactor tetrahydrobiopterin, BH4, is also essential for eNOS coupling...
2017: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29163139/exercise-induced-neuroprotection-of-the-nigrostriatal-dopamine-system-in-parkinson-s-disease
#4
REVIEW
Lijuan Hou, Wei Chen, Xiaoli Liu, Decai Qiao, Fu-Ming Zhou
Epidemiological studies indicate that physical activity and exercise may reduce the risk of developing Parkinson's disease (PD), and clinical observations suggest that physical exercise can reduce the motor symptoms in PD patients. In experimental animals, a profound observation is that exercise of appropriate timing, duration, and intensity can reduce toxin-induced lesion of the nigrostriatal dopamine (DA) system in animal PD models, although negative results have also been reported, potentially due to inappropriate timing and intensity of the exercise regimen...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29158414/molecular-basis-of-selective-resistance-of-the-bumblebee-binav1-sodium-channel-to-tau-fluvalinate
#5
Shaoying Wu, Yoshiko Nomura, Yuzhe Du, Boris S Zhorov, Ke Dong
Insecticides are widely used to control pests in agriculture and insect vectors that transmit human diseases. However, these chemicals can have a negative effect on nontarget, beneficial organisms including bees. Discovery and deployment of selective insecticides is a major mission of modern toxicology and pest management. Pyrethroids exert their toxic action by acting on insect voltage-gated sodium channels. Honeybees and bumblebees are highly sensitive to most pyrethroids, but are resistant to a particular pyrethroid, tau-fluvalinate (τ-FVL)...
November 20, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29157654/an-innovative-lung-model-for-multiple-breath-washout-testing-in-health-and-disease
#6
Pinelopi Anagnostopoulou, Sarah Vomsattel, Anne-Christiane Kentgens, Marisa Guidi, Severin Binggeli, Lena Kohler, Florian Singer, Philipp Latzin, Dominik Obrist
BACKGROUND: Multiple breath washout (MBW) is a lung function test that identifies the degree of ventilation inhomogeneity (VI) in the lungs. In vitro validation of MBW devices is recommended. So far, plastic lung models for MBW validation ignored variable degrees of VI. Our primary aim was to create a plastic lung model applicable for physiological lung volumes and variable VI. METHODS: A plastic box divided in two chambers was filled with water and ventilated in various lung volumes and respiratory rates...
November 10, 2017: Clinical Biomechanics
https://www.readbyqxmd.com/read/29156604/takamatsu-h-comparison-of-minimal-residual-disease-detection-by-multiparameter-flow-cytometry-aso-qpcr-droplet-digital-pcr-and-deep-sequencing-in-patients-with-multiple-myeloma-who-underwent-autologous-stem-cell-transplantation-j-clin-med-2017-6-91
#7
https://www.readbyqxmd.com/read/29156204/autologous-hematopoietic-cell-transplantation-for-adult-acute-myeloid-leukemia-an-obsolete-or-resurfacing-concept
#8
REVIEW
Hillard M Lazarus, Najla El Jurdi
Improving long-term outcomes of adult acute myeloid leukemia (AML) patients remains a challenge. Major scientific and clinical advances have led to a better understanding of the disease biology, and the majority of patients achieve a complete remission (CR) after induction therapy. Relapse risk, however, remains considerable and is the leading cause of death in this patient population. Significant efforts to improve outcomes emphasize use of post-remission therapies such as hematopoietic cell transplantation (HCT), an increasingly utilized modality...
December 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29156202/relapsed-acute-lymphoblastic-leukemia-is-it-crucial-to-achieve-molecular-remission-prior-to-transplant
#9
REVIEW
Mary Eapen
In patients with acute lymphoblastic leukemia (ALL) the risk of recurrent leukemia influences the choice of treatment between chemotherapy and allogeneic hematopoietic cell transplantation. The evaluation of minimal residual disease (MRD) is now considered to be the greatest progress in risk stratification in regard to leukemia recurrence. Achieving molecular remission at the end of induction therapy after diagnosis or after relapse has influenced treatment choice. Failure to achieve molecular remission is considered "high risk" and allogeneic hematopoietic cell transplantation with a suitable donor, the accepted standard...
December 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29156195/aml-in-2017-advances-in-clinical-practice
#10
REVIEW
Jacob M Rowe
Numerous advances have been made in the biology and treatment of acute myeloid leukemia (AML) in 2017. These include the integration of the assessment of minimal residual disease (MRD) into clinical practice, the approval and near approval of new agents, improvement in therapy for older patients, and the development of a number of promising new agents, including IDH inhibitors, a Hedgehog signaling pathway inhibitor, and a histone deacetylase inhibitor. In addition, the concept of chemotherapy manipulation is still valid and can increase efficacy in some AML populations, and transplant patterns have shifted, enabling more patients to receive a hematopoietic stem cell transplant...
December 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29151258/clinical-significance-of-disease-specific-myd88-mutations-in-circulating-dna-in-primary-central-nervous-system-lymphoma
#11
Keiichiro Hattori, Mamiko Sakata-Yanagimoto, Yasuhito Suehara, Yasuhisa Yokoyama, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Naoshi Obara, Shingo Takano, Eiichi Ishikawa, Akira Matsumura, Yuichi Hasegawa, Shigeru Chiba
Recent sequencing studies demonstrated the MYD88 L265P mutation in more than 70% of primary central nervous system lymphomas (PCNSL), and the clinical significance of this mutation has been proposed as diagnostic and prognostic markers in PCNSL. On the other hand, mutational analyses using cell-free DNAs have been reported in a variety of systemic lymphomas. To investigate how sensitively the MYD88 L265P mutation can be identified in cell-free DNA from PCNSL patients, we performed droplet digital PCR (ddPCR) and targeted deep sequencing (TDS) in consecutive 14 PCNSL patients from whom paired tumor-derived DNA and cell-free DNA was available at diagnosis...
November 19, 2017: Cancer Science
https://www.readbyqxmd.com/read/29148893/reduced-intensity-delayed-intensification-in-standard-risk-pediatric-acute-lymphoblastic-leukemia-defined-by-undetectable-minimal-residual-disease-results-of-an-international-randomized-trial-aieop-bfm-all-2000
#12
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, Andrea Biondi, Anja Möricke, Franco Locatelli, Gunnar Cario, Carmelo Rizzari, Andishe Attarbaschi, Maria Grazia Valsecchi, Claus R Bartram, Elena Barisone, Felix Niggli, Charlotte Niemeyer, Anna Maria Testi, Georg Mann, Ottavio Ziino, Beat Schäfer, Renate Panzer-Grümayer, Rita Beier, Rosanna Parasole, Gudrun Göhring, Wolf-Dieter Ludwig, Fiorina Casale, Paul-Gerhardt Schlegel, Giuseppe Basso, Valentino Conter
Purpose Delayed intensification (DI) is an integral part of treatment of childhood acute lymphoblastic leukemia (ALL), but it is associated with relevant toxicity. Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity. Patients and Methods Between July 2000 and July 2006, 1,164 patients (1 to 17 years of age) with standard-risk ALL (defined as the absence of high-risk cytogenetics and undetectable minimal residual disease on days 33 and 78) were randomly assigned to either experimental reduced-intensity DI (protocol III; P-III) or standard DI (protocol II; P-II)...
November 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29145456/regulation-of-the-bone-marrow-microenvironment-by-g-csf-effects-of-g-csf-on-acute-lymphoblastic-leukaemia
#13
Jordan Basnett, Vicki Xie, Adam Cisterne, Ken Bradstock, Linda Bendall
It has been suggested that disruption of the lymphoid niche by G-CSF may be of therapeutic benefit to patients with acute lymphoblastic leukaemia. We used a xenograft model to determine the effect of G-CSF on ALL progression in a minimal residual disease setting. Consistent with the effects on normal murine B cell progenitors, G-CSF slowed disease in the majority of ALL xenografts tested, suggesting that G-CSF may provide benefits beyond neutrophil recovery for ALL patients. However, two of eight xenografts demonstrated accelerated disease progression...
2017: PloS One
https://www.readbyqxmd.com/read/29143423/treatment-and-biology-of-pediatric-acute-lymphoblastic-leukemia
#14
REVIEW
Motohiro Kato, Atsushi Manabe
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past ALL was intractable but now the survival probability is as high as 80-90%. Improved supportive care, treatment stratification based on relapse risk, biological features of leukemic cells, and optimization of treatment regimens by nationwide and international collaboration have contributed to this dramatic improvement. While including traditional risk factors (e.g., age and leukocyte count at diagnosis), the treatment has been modified based on biological characteristics (aneuploidy and translocation) and treatment response (assessed by minimal residual disease)...
November 16, 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/29137972/circulating-tumoral-dna-preanalytical-validation-and-quality-control-in-a-diagnostic-laboratory
#15
Sergey Nikolaev, Laure Lemmens, Thibaud Koessler, Jean-Louis Blouin, Thierry Nouspikel
We present the results of our technical validation process in establishing the analysis of circulating tumor DNA (ctDNA) as a diagnostic tool. Like most cells in our body, tumor cells shed DNA in the blood flow. Analysis of ctDNA mutational content can provide invaluable information on the genetic makeup of a tumor, and assist oncologists in deciding on therapy, or in following residual disease. However, low absolute amounts of circulating DNA and low tumor fraction constitute formidable analytical challenges...
November 11, 2017: Analytical Biochemistry
https://www.readbyqxmd.com/read/29133595/targeted-next-gen-sequencing-for-detecting-mll-gene-fusions-in-leukemia
#16
Sadia Afrin, Christine Rc Zhang, Claus Meyer, Caedyn L Stinson, Thy Pham, Timothy Jc Bruxner, Nicola C Venn, Toby N Trahair, Rosemary Sutton, Rolf Marschalek, J Lynn Fink, Andrew S Moore
Mixed Lineage Leukemia (MLL) gene rearrangements characterize approximately 70% of infant and 10% of adult and therapy-related leukemia. Conventional clinical diagnostics, including cytogenetics and fluorescence in situ hybridization (FISH) fail to detect MLL translocation partner genes (TPGs) in many patients. Long-Distance Inverse (LDI)-PCR, the 'gold standard' technique that is used to characterize MLL breakpoints is laborious and requires a large input of genomic DNA (gDNA). To overcome the limitations of current techniques, a targeted Next-Generation Sequencing (NGS) approach that requires low RNA input was tested...
November 13, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29131700/integrated-risk-stratification-using-minimal-residual-disease-and-sentinel-genetic-alterations-in-pediatric-acute-lymphoblastic-leukemia
#17
Stephen P Hunger
No abstract text is available yet for this article.
November 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29131699/genotype-specific-minimal-residual-disease-interpretation-improves-stratification-in-pediatric-acute-lymphoblastic-leukemia
#18
David O'Connor, Amir Enshaei, Jack Bartram, Jeremy Hancock, Christine J Harrison, Rachael Hough, Sujith Samarasinghe, Claire Schwab, Ajay Vora, Rachel Wade, John Moppett, Anthony V Moorman, Nick Goulden
Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduces predictive accuracy. The aim of our study was to exploit the full power of MRD by examining it as a continuous variable and to integrate it with genetics. Patients and Methods We used a population-based cohort of 3,113 patients who were treated in UKALL2003, with a median follow-up of 7 years...
November 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29128071/diagnosis-of-plasma-cell-dyscrasias-and-monitoring-of-minimal-residual-disease-by-multiparametric-flow-cytometry
#19
REVIEW
Kah Teong Soh, Joseph D Tario, Paul K Wallace
Plasma cell dyscrasia (PCD) is a heterogeneous disease that has seen a tremendous change in outcomes due to improved therapies. Over the past few decades, multiparametric flow cytometry has played an important role in the detection and monitoring of PCDs. Flow cytometry is a high-sensitivity assay for early detection of minimal residual disease (MRD) that correlates well with progression-free survival and overall survival. Before flow cytometry can be effectively implemented in the clinical setting, sample preparation, panel configuration, analysis, and gating strategies must be optimized to ensure accurate results...
December 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29128069/how-do-we-use-multicolor-flow-cytometry-to-detect-minimal-residual-disease-in-acute-myeloid-leukemia
#20
REVIEW
Jie Xu, Jeffrey L Jorgensen, Sa A Wang
Multicolor flow cytometry (MFC), combined with molecular and cytogenetic studies, is the most common method for detecting minimal residual disease (MRD) in acute myeloid leukemia (AML). Studies have shown that a positive MFC MRD study after induction and/or consolidation, or before allogeneic hematopoietic stem cell transplantation, correlates with risk of relapse and inferior survival. However, there is little information on technical and analytical details. This article shares the authors' experience using MFC for AML MRD detection, including antibody panel design, data analysis, and interpretation...
December 2017: Clinics in Laboratory Medicine
keyword
keyword
10194
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"